On November 21, 2013, AHRMM submitted electronically
Filter your results:
6 Results Found
AHRMM Comment Letter to FDA Regarding the Draft Guidance for Industry on the Global Unique Device Identification Database (GUDID)
AHRMM supports the concept and use of Comparative Effectiveness Research (CER) to provide evidence-based data to help inform purchasing decisions. CER is designed to support healthcare decisions by providing objective conclusions after comparing the effectiveness, benefits, and potential harm of various medical equipment, devices, or treatment options for specific episodes of care or states of disease. By using objective data provided by CER, healthcare supply chain professionals have the ability to:
This document is intended to provide information about submitting data to the database for device Labelers, entities responsible for providing the data to the GUDID. Download Now
The Internal Revenue Service released a
AHA Special Bulletin on the Centers for Medicare & Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC) guidance adding roadblocks for hospitals working to become meaningful users of electronic health records (EHRs) and receive incentive payments promised in the stimulus bill.
The Official Comment of AHRMM to the United States Department of Health and Human Services Food and Drug Administration (FDA) regarding Unique Device Identification for Medical Devices Docket No. FDA-2011-N-0090
AHRMM comments to the FDA regarding an amendment to the UDI proposed rule to address the UDI implementation time frame required by the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA).